GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Veracyte Inc (NAS:VCYT) » Definitions » Debt-to-EBITDA

Veracyte (Veracyte) Debt-to-EBITDA

: -0.13 (As of Dec. 2023)
View and export this data going back to 2013. Start your Free Trial

Debt-to-EBITDA measures a company's ability to pay off its debt.

Veracyte's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $5.1 Mil. Veracyte's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $7.5 Mil. Veracyte's annualized EBITDA for the quarter that ended in Dec. 2023 was $-96.5 Mil. Veracyte's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.13.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Veracyte's Debt-to-EBITDA or its related term are showing as below:

VCYT' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.74   Med: -0.74   Max: -0.16
Current: -0.26

During the past 13 years, the highest Debt-to-EBITDA Ratio of Veracyte was -0.16. The lowest was -1.74. And the median was -0.74.

VCYT's Debt-to-EBITDA is ranked worse than
100% of 106 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.8 vs VCYT: -0.26

Veracyte Debt-to-EBITDA Historical Data

The historical data trend for Veracyte's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Veracyte Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.74 -0.46 -0.31 -1.43 -0.26

Veracyte Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.18 -2.44 -2.63 -0.15 -0.13

Competitive Comparison

For the Diagnostics & Research subindustry, Veracyte's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Veracyte Debt-to-EBITDA Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Veracyte's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Veracyte's Debt-to-EBITDA falls into.



Veracyte Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Veracyte's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(5.105 + 7.525) / -49.409
=-0.26

Veracyte's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(5.105 + 7.525) / -96.536
=-0.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Veracyte  (NAS:VCYT) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Veracyte Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Veracyte's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Veracyte (Veracyte) Business Description

Traded in Other Exchanges
Address
6000 Shoreline Court, Suite 300, South San Francisco, CA, USA, 94080
Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others. The company derives its revenues from the Sale of Afirma analysis products.
Executives
Phillip G. Febbo officer: Chief Scientific & Med Officer C/O GENOMIC HEALTH, INC., 301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
John Leite officer: Chief Commercial Officer-CLIA 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Evan/ Fa Jones director C/O OPGEN, INC., 708 QUINCE ORCHARD ROAD, SUITE 205, GAITHERSBURG MD 20878
John L Bishop director
Muna Bhanji director C/O CYTOKINETICS, INCORPORATED, 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Bonnie H Anderson director, officer: President & CEO 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Karin Eastham director C/O BURNHAM INSTITUTE FOR MEDICAL RESEAR, 10901 N. TORREY PINES ROAD, LA JOLLA CA 92037
Giulia C Kennedy officer: Chief Scientific & Med Officer 338 MAIN STREET #26E, SAN FRANCISCO CA 94105
Eliav Barr director C/O VERACYTE, INC., 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Jens Holstein director C/O VERACYTE, INC., 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Marc Stapley officer: Chief Executive Officer 9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
Kevin K Gordon director 155 S LIMERICK RD, LIMERICK PA 19468
Jonathan Wygant officer: VP, Chief Accounting Officer 3750 TORREY VIEW COURT, SAN DIEGO X1 92130
Annie Mcguire officer: SVP, General Counsel C/O VERACYTE, INC., 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Rebecca Chambers officer: Chief Financial Officer 3052 ORCHARD DR., SAN JOSE CA 95134

Veracyte (Veracyte) Headlines